{"id":"ni-071","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL5998520","moleculeType":null,"molecularWeight":"393.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting PDE9, NI-071 prevents the breakdown of cyclic GMP, leading to enhanced intracellular signaling that may improve cognitive function and neuroplasticity. This mechanism is being investigated for neurodegenerative and cognitive disorders where PDE9 inhibition may provide neuroprotective or cognitive-enhancing effects.","oneSentence":"NI-071 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:22:57.005Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment associated with schizophrenia"}]},"trialDetails":[{"nctId":"NCT02990806","phase":"PHASE3","title":"A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)","status":"COMPLETED","sponsor":"Nichi-Iko Pharmaceutical Co., Ltd.","startDate":"2017-01-19","conditions":"Rheumatoid Arthritis","enrollment":683},{"nctId":"NCT01927263","phase":"PHASE3","title":"A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Nichi-Iko Pharmaceutical Co., Ltd.","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":242},{"nctId":"NCT01931189","phase":"PHASE1","title":"Pharmacokinetics Study of NI-071","status":"COMPLETED","sponsor":"Nichi-Iko Pharmaceutical Co., Ltd.","startDate":"2013-08","conditions":"Healthy","enrollment":96},{"nctId":"NCT01567358","phase":"PHASE1","title":"Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Nichi-Iko Pharmaceutical Co., Ltd.","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NI-071","genericName":"NI-071","companyName":"Nichi-Iko Pharmaceutical Co., Ltd.","companyId":"nichi-iko-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NI-071 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system. Used for Cognitive impairment associated with schizophrenia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}